Urinary Oxidative Stress Biomarker Levels Might Be Useful in Identifying Functional Bladder Disorders in Women with Frequency and Urgency Syndrome

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Mar 29

PMID 36983336

Authors

Yuan-Hong Jiang

Jia-Fong Jhang

Hann-Chorng Kuo

Affiliations

Soon will be listed here.

Abstract

Purpose: lower urinary tract dysfunctions (LUTDs) are difficult to diagnose based on symptoms. This study used a cluster of urinary biomarkers, including inflammatory cytokines, neurogenic proteins, and oxidative stress biomarkers, to identify LUTDs in women with frequency and urgency symptoms.

Methods: in total, 253 women with video urodynamics (VUDS)- and cystoscopy-confirmed detrusor overactivity (DO), interstitial cystitis/bladder pain syndrome (IC/BPS), dysfunctional voiding (DV), and hypersensitive bladder (HSB), and normal controls were included. Before diagnosis and treatment, urine samples were collected for analysis of biomarkers. The urine levels of biomarkers were compared between groups with bladder dysfunctions and controls and were combined to test the sensitivity in identifying total pathological bladder diseases and specific bladder diseases.

Results: After video urodynamic study, VUDS, and urological examinations, bladder dysfunctions were classified into DO ( = 31), IC/BPS ( = 114), DV ( = 45), HSB ( = 29), and control ( = 34) groups. By using a cystomeric bladder capacity of ≤350 mL, 186/219 (84.9%) of the patients with DO, IC/BPS, DV, and HSB can be discriminated from the controls. Among these urine biomarkers, oxidative stress biomarkers 8-isoprostane, 8-hydroxydeoxyguanosine (8-OHdG), or total antioxidant capacity (TAC) are useful for identifying pathological bladder dysfunction (DO, IC/BPS, and DV) and HSB. With elevated IL-1β and lower IL-2, and elevated TNF-α levels, most patients with DV can be identified. Between DO and IC/BPS, a higher NGF level can identify 58.3% of IC/BPS cases, whereas a lower NGF level can identify 75.0% of DO cases.

Conclusion: by using a cluster of urine biomarkers, DO, IC/BPS, and DV cases can be identified based on elevated levels of urine oxidative stress biomarkers 8-isoprostane, TAC, or 8-OHdG, and HSB cases with a low TAC. These urine biomarkers are useful for identifying specific LUTDs in women with frequency and urgency symptoms.

Citing Articles

Integrating biomarker clustering for improved diagnosis of interstitial cystitis/bladder pain syndrome: a review.

Chen Y, Kuo H Int Urol Nephrol. 2025; .

PMID: 40088357 DOI: 10.1007/s11255-025-04452-y.

Using Urine Biomarkers to Differentiate Bladder Dysfunctions in Women with Sensory Bladder Disorders.

Chen Y, Jiang Y, Jhang J, Kuo H Int J Mol Sci. 2024; 25(17).

PMID: 39273307 PMC: 11395209. DOI: 10.3390/ijms25179359.

Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction.

Yu W, Jiang Y, Jhang J, Kuo H Tzu Chi Med J. 2024; 36(2):110-119.

PMID: 38645782 PMC: 11025593. DOI: 10.4103/tcmj.tcmj_221_23.

References

Pontari M, Hanno P, Ruggieri M . Comparison of bladder blood flow in patients with and without interstitial cystitis. J Urol. 1999; 162(2):330-4. View

Wang H, Kuo H . Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice. Tzu Chi Med J. 2022; 34(4):441-447. PMC: 9791855. DOI: 10.4103/tcmj.tcmj_264_20. View

Siddiqui N, Helfand B, Andreev V, Kowalski J, Bradley M, Lai H . Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses. J Urol. 2019; 202(5):880-889. PMC: 6766427. DOI: 10.1097/JU.0000000000000257. View

Speich J, Tarcan T, Hashitani H, Vahabi B, McCloskey K, Andersson K . Are oxidative stress and ischemia significant causes of bladder damage leading to lower urinary tract dysfunction? Report from the ICI-RS 2019. Neurourol Urodyn. 2020; 39 Suppl 3:S16-S22. PMC: 9794413. DOI: 10.1002/nau.24313. View

Lin H, Lu J, Chuang S, Chueh K, Juan T, Liu Y . Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome. Diagnostics (Basel). 2022; 12(1). PMC: 8774507. DOI: 10.3390/diagnostics12010075. View

Kim J, Kim W, Kim W . Advances in urinary biomarker discovery in urological research. Investig Clin Urol. 2020; 61(Suppl 1):S8-S22. PMC: 7004831. DOI: 10.4111/icu.2020.61.S1.S8. View

Lee J, Lee M . Increased expression of hypoxia-inducible factor-1α and vascular endothelial growth factor associated with glomerulation formation in patients with interstitial cystitis. Urology. 2011; 78(4):971.e11-5. DOI: 10.1016/j.urology.2011.05.050. View

Kim J, de Hoedt A, Wiggins E, Haywood K, Jin P, Greenwood B . Diagnostic Utility of Serum and Urinary Metabolite Analysis in Patients with Interstitial Cystitis/Painful Bladder Syndrome. Urology. 2021; 157:85-92. PMC: 10461181. DOI: 10.1016/j.urology.2021.05.005. View

Wu Y, Chueh K, Chuang S, Long C, Lu J, Juan Y . Bladder Hyperactivity Induced by Oxidative Stress and Bladder Ischemia: A Review of Treatment Strategies with Antioxidants. Int J Mol Sci. 2021; 22(11). PMC: 8199707. DOI: 10.3390/ijms22116014. View

10.

Jiang Y, Jhang J, Ho H, Chiou D, Kuo H . Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome. Biomedicines. 2022; 10(7). PMC: 9312927. DOI: 10.3390/biomedicines10071701. View

11.

Chuang F, Huang K, Kuo H . Lower Urinary Tract Symptoms and Video-Urodynamic Characteristics of Women with Clinically Unsuspected Bladder Outlet Obstruction. Low Urin Tract Symptoms. 2015; 5(1):23-7. DOI: 10.1111/j.1757-5672.2012.00160.x. View

12.

Miyazaki N, Katsura R, Hamada K, Suzutani T . Blueberry Prevents the Bladder Dysfunction in Bladder Outlet Obstruction Rats by Attenuating Oxidative Stress and Suppressing Bladder Remodeling. Nutrients. 2020; 12(5). PMC: 7282255. DOI: 10.3390/nu12051285. View

13.

Silva A, Dinis P, Abranches Monteiro L . Systematic review of urinary biomarkers of female bladder outlet obstruction (fBOO). Arch Ital Urol Androl. 2022; 94(3):355-359. DOI: 10.4081/aiua.2022.3.355. View

14.

Lee C, Chen S, Jiang Y, Kuo H . Effect of videourodynamic subtypes on treatment outcomes of female dysfunctional voiding. Int Urogynecol J. 2022; 33(5):1283-1291. DOI: 10.1007/s00192-022-05154-0. View

15.

Chow P, Kuo H . Performance of urinary biomarkers in differentiating dysfunctional voiding in women with overactive bladder syndrome: a prospective pilot study. Int Urol Nephrol. 2022; 54(10):2497-2502. DOI: 10.1007/s11255-022-03265-7. View

16.

Peng C, Chen S, Kuo H . Videourodynamic analysis of the urethral sphincter overactivity and the poor relaxing pelvic floor muscles in women with voiding dysfunction. Neurourol Urodyn. 2017; 36(8):2169-2175. DOI: 10.1002/nau.23263. View

17.

Dokumacioglu E, Demiray O, Dokumacioglu A, Sahin A, Sen T, Cankaya S . Measuring urinary 8-hydroxy-2'-deoxyguanosine and malondialdehyde levels in women with overactive bladder. Investig Clin Urol. 2018; 59(4):252-256. PMC: 6028472. DOI: 10.4111/icu.2018.59.4.252. View

18.

Schieber M, Chandel N . ROS function in redox signaling and oxidative stress. Curr Biol. 2014; 24(10):R453-62. PMC: 4055301. DOI: 10.1016/j.cub.2014.03.034. View

19.

Kuo H . Clinical symptoms are not reliable in the diagnosis of lower urinary tract dysfunction in women. J Formos Med Assoc. 2012; 111(7):386-91. DOI: 10.1016/j.jfma.2011.05.014. View

20.

Lai H, Pickersgill N, Vetter J . Hunner Lesion Phenotype in Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis. J Urol. 2020; 204(3):518-523. DOI: 10.1097/JU.0000000000001031. View